If all goes to plan, the International Medical Device Regulators Forum will have completed by July a draft guidance that explores when and to what level clinical evaluation and evidence is necessary or acceptable to support marketing authorizations of software as a medical device (SaMD)1.
The draft document is being developed to address the current confusion over – and the lack of guidance on – what clinical data is appropriate for the uniqueness of medical...